Business
iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain
Zio long-term continuous monitoring (LTCM) service consists of a prescription only patch ECG monitoring device (Zio® monitor) worn for up to 14 days, the ZEUS
About this update from Irhythm Holdings, Inc.
[{"type":"text","content":"Zio long-term continuous monitoring (LTCM) service consists of a prescription only patch ECG monitoring device (Zio® monitor) worn for up to 14 days, the ZEUS (Zio ECG Utilization Software) System (iRhythm’s advanced AI algorithm), and a comprehensive end-of-wear report reviewed and curated by certified cardiographic technicians.The next-generation Zio monitor LTCM provides up to 14 days of continuous, uninterrupted, patch-based ECG monitoring, marking a significant advancement in these countries, compared to older, commonly used 24- to 48-hour (Holter) monitoring technology1. Zio LTCM is associated with a greater diagnostic yield of specified arrhythmias, the lowest likelihood of retesting and the lowest incremental acute care utilization, as compared to Holter monitoring services1,2,3,4.Zio products and services are backed by over 100 peer-reviewed clinical research and scientific papers5. SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the commercial launch of its Zio® monitor and Zio® long-term continuous (LTCM) ambulatory ECG monitoring service in Austria, the Netherlands, Spain, and Switzerland. The Zio monitor and ZEUS (Zio ECG Utilization Software) system received the European Union’s CE Marking Under Medical Device Regulation (EU MDR) in December 2023. The Zio LTCM service provides up to 14 days of continuous, uninterrupted ECG monitoring, marking a significant advancement in these countries, compared to older, commonly used 24- to 48-hour Holter monitoring services1. “Expanding access to our innovative Zio cardiac arrhythmia monitoring system and services for millions more people in Europe is an important milestone for iRhythm’s patient-first mission to positively impact people across the globe,” said Quentin Blackford, iRhythm President and CEO. “Our commitment extends to broadening our highly innovative digital healthcare solutions, while ensuring they are cost-effective and accessible worldwide.” Advancing Cardiac Care in Europe Zio LTCM service offers a range of distinct advantages that set it apart as a leading solution for cardiac monitoring in Europe: Up to 14 days of continuous, uninterrupted ECG monitoring99% patient compliance with pr...